The news that an Air India pilot reportedly tested positive for cannabis during a routine screening has triggered a familiar, visceral reaction. In aviation, where public safety demands absolute sobriety, any hint of cognitive impairment is understandably met with swift scrutiny. Yet, beneath the immediate headlines lies a more complex scientific reality—one that challenges our reliance on simple binary tests to measure human capability.
Unlike alcohol, which clears the bloodstream within hours, chemical traces of cannabis can linger in the human body for days or even weeks after use. A positive urine test indicates exposure, but it remains notoriously silent on the question of active impairment. It cannot tell investigators whether a pilot was under the influence while in the cockpit, or if they merely spent an evening in a legal jurisdiction days prior.
As global attitudes and legal frameworks surrounding cannabis continue to evolve, the aviation industry faces a delicate modern dilemma. Ensuring sky-high safety standards is non-negotiable, but relying on blunt analytical tools risks conflating historical lifestyle choices with immediate operational risk. To truly protect the skies, aviation safety must begin to look beyond the mere presence of molecules, searching instead for more precise metrics of active cognitive readiness.